


## CLAIMS

**1. Use of a compound for the manufacture of a medicament for the treatment and/or the prevention of an HDAC6-associated disease;**


wherein said compound is a compound of formula (I)



or a pharmaceutically acceptable salt and/or solvate thereof;

wherein

-  $Y^1$  is a 9- or 10-membered bicyclic heteroaryl selected from the following formulae



wherein

**A**<sup>1</sup>, **A**<sup>2</sup>, **A**<sup>3</sup>, **A**<sup>4</sup>, **A**<sup>5</sup>, **A**<sup>6</sup> and **A**<sup>7</sup> are each independently selected from C-**R**<sup>7</sup> and N;

**A**<sup>8</sup>, **A**<sup>9</sup>, **A**<sup>10</sup> and **A**<sup>11</sup> are each independently selected from C-**R**<sup>7</sup> and N, provided that at least one of **A**<sup>8</sup>, **A**<sup>9</sup>, **A**<sup>10</sup> or **A**<sup>11</sup> is N;

**G**<sup>1</sup> is selected from C-**R**<sup>3</sup> and N;

**G**<sup>2</sup> is selected from O and N-**R**<sup>4</sup>;

**B** is selected from O, S and N-**R**<sup>5</sup>,

provided that when **A**<sup>5</sup>, **A**<sup>6</sup> and **A**<sup>7</sup> are C-**R**<sup>7</sup>, then **B** is not S; and

**R**<sup>2</sup> is selected from hydrogen, halogen, cyano, amino, hydroxy, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>-SO<sub>2</sub>-R<sup>15</sup>, -C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -C(O)-R<sup>15</sup>, -C(O)OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>;

**R**<sup>3</sup> is selected from halogen, cyano, amino, hydroxy, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>-SO<sub>2</sub>-R<sup>15</sup>, -C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -C(O)-R<sup>15</sup>, -C(O)OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>;

**R**<sup>4</sup> is selected from hydrogen, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-aryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-

C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, and -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup>;

R<sup>5</sup> is selected from hydrogen, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-aryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, and -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup>;

R<sup>7</sup> is independently selected from hydrogen, halogen, amino, hydroxy, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>16</sup>(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -SO-R<sup>15</sup>, -SO<sub>2</sub>-R<sup>15</sup>, -SO<sub>2</sub>NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>-SO<sub>2</sub>-R<sup>15</sup>, -C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>C(O)-R<sup>15</sup>, -C(O)-R<sup>15</sup>, -C(O)-OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-OR<sup>15</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-OR<sup>15</sup>, -OC(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup> or -NR<sup>16</sup>-C(O)-OR<sup>15</sup>;

wherein

each of said -(C<sub>1</sub>-C<sub>6</sub>) alkyl or -(C<sub>1</sub>-C<sub>6</sub>) alkylene in R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> or R<sup>7</sup> is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;

each of said -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl or heteroaryl in R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> or R<sup>7</sup> is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;


R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> are each independently selected from hydrogen, -(C<sub>1</sub>-C<sub>6</sub>) haloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-heteroaryl, and -(C<sub>1</sub>-C<sub>6</sub>) alkylene-aryl; and/or two groups selected from R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> form together a cycle selected from -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl and heteroaryl;

wherein

each of said  $-(C_1-C_6)$  alkyl or  $-(C_1-C_6)$  alkylene in  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$  or  $R^{18}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

each of said  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl or heteroaryl in  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$  or  $R^{18}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6) \text{ alkyl})_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

-  $Y^2$  is a 5-membered heteroaryl selected from the following formulae



wherein  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  are each independently selected from hydrogen, halogen, cyano, hydroxy, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6) \text{ alkyl})_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

wherein each of said  $-(C_1-C_6)$  alkyl in  $R^{12}$ ,  $R^{13}$  or  $R^{14}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

-  $L$  is selected from  $-(CR^{10}R^{11})_n$ ,  $-(C_3-C_7)$  cycloalkyl and  $(C_3-C_7)$  heterocycloalkyl;

wherein

$n$  is an integer selected from 1, 2, 3 and 4;

$R^{10}$  and  $R^{11}$  are independently selected from hydrogen, halogen, hydroxy, amino,  $-(C_1-C_3)$  alkyl,  $-(C_1-C_2)$  haloalkyl,  $-(C_1-C_2)$  hydroxyalkyl,  $-(C_1-C_2)$  aminoalkyl,  $-O-(C_1-C_4)$  alkyl,  $-NH-(C_1-C_3)$  alkyl and  $-N-((C_1-C_3) \text{ alkyl})_2$ ;

each of said  $-(C_3-C_7)$  cycloalkyl or  $(C_3-C_7)$  heterocycloalkyl in  $L$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6) \text{ alkyl})_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

-  $Z^1$  is selected from  $(C=O)-R^9$  and  $S(O_2)-R^9$ ;

wherein  $R^9$  is selected from amino,  $-(C_1-C_6)$  alkyl,  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl, heteroaryl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  cycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  heterocycloalkyl,  $-(C_1-C_6)$  alkylene-aryl,  $-(C_1-C_6)$  alkylene-heteroaryl,  $-(C_1-C_6)$  alkylene- $OR^{21}$ ,  $-(C_1-C_6)$  alkylene- $NR^{23}R^{24}$ ,  $-(C_1-C_6)$  alkylene- $C(O)-NR^{23}R^{24}$ ,  $-(C_1-C_6)$  alkylene- $C(O)-NR^{23}R^{24}$ ,  $-(C_1-C_6)$  alkylene- $NR^{22}-C(O)-R^{21}$ ,  $-(C_1-C_6)$  alkylene- $C(O)OR^{21}$ ,  $-OR^{21}$ ,  $-NR^{23}R^{24}$ ,  $-NR^{22}-(C_2-C_6)$  alkylene- $OR^{21}$ ,  $-NR^{22}-(C_2-C_6)$  alkylene- $NR^{23}R^{24}$ ,  $-NR^{22}-(C_1-C_6)$  alkylene- $C(O)OR^{21}$ ;

wherein

each of said  $-(C_1-C_6)$  alkyl or  $-(C_1-C_6)$  alkylene in  $R^9$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

each of said  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl or heteroaryl in  $R^9$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6) \text{ alkyl})_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  are each independently selected from hydrogen,  $-(C_1-C_6)$  alkyl,  $-(C_3-C_7)$  cycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  cycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  heterocycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl, heteroaryl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  heterocycloalkyl,  $-(C_1-C_6)$  alkylene-heteroaryl, and  $-(C_1-C_6)$  alkylene-aryl; and/or two groups selected from  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  form together a cycle selected from  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl and heteroaryl;

wherein

each of said  $-(C_1-C_6)$  alkyl or  $-(C_1-C_6)$  alkylene in  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  or  $R^{24}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

each of said  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl or heteroaryl in  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  or  $R^{24}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6) \text{ alkyl})_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ; and

$-R^1$  is selected from hydrogen,  $-(C_1-C_6)$  alkyl,  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  cycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  heterocycloalkyl,  $-(C_1-C_6)$  alkylene- $OR^{19}$  and  $-(C_1-C_6)$  alkylene- $NR^{19}R^{20}$ ,

wherein

**R<sup>19</sup>** and **R<sup>20</sup>** are each independently selected from hydrogen, -(C<sub>1</sub>-C<sub>6</sub>) alkyl and -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl; or **R<sup>19</sup>** and **R<sup>20</sup>** form together a cycle selected from -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl and -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl;

each of said -(C<sub>1</sub>-C<sub>6</sub>) alkyl or -(C<sub>1</sub>-C<sub>6</sub>) alkylene in **R<sup>1</sup>**, **R<sup>19</sup>** and **R<sup>20</sup>** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;

each of said -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl or -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl in **R<sup>15</sup>**, **R<sup>16</sup>**, **R<sup>17</sup>** or **R<sup>18</sup>** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;


**R<sup>1</sup>** and one of **R<sup>10</sup>** or **R<sup>11</sup>** form together a (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl comprising at least one nitrogen atom;

wherein said (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl in **R<sup>1</sup>** and **R<sup>10</sup>** or **R<sup>11</sup>** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>; or

**R<sup>1</sup>** and **R<sup>9</sup>** form together a (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl comprising at least one nitrogen atom;

wherein said (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl in **R<sup>1</sup>** and **R<sup>9</sup>** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>.


## 2. A compound of formula (I)



or a pharmaceutically acceptable salt and/or solvate thereof;

wherein

-  $Y^1$  is a 9- or 10-membered bicyclic heteroaryl selected from the following formulae



wherein

$A^1$ ,  $A^2$ ,  $A^3$ ,  $A^4$ ,  $A^5$ ,  $A^6$  and  $A^7$  are each independently selected from C- $R^7$  and N;

$A^8$ ,  $A^9$ ,  $A^{10}$  and  $A^{11}$  are each independently selected from C- $R^7$  and N, provided that at least one of  $A^8$ ,  $A^9$ ,  $A^{10}$  or  $A^{11}$  is N;

$G^1$  is selected from C- $R^3$  and N;

$G^2$  is selected from O and N- $R^4$ ;

**B** is selected from O, S and N- $R^5$ ,

provided that when  $A^5$ ,  $A^6$  and  $A^7$  are C- $R^7$ , then **B** is not S; and

$R^2$  is selected from hydrogen, halogen, cyano, amino, hydroxy,  $-(C_1-C_6)$  alkyl,  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl, heteroaryl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  cycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  heterocycloalkyl,  $-OR^{15}$ ,  $-(C_1-C_6)$  alkylene- $OR^{15}$ ,  $-O-(C_2-C_6)$  alkylene- $OR^{15}$ ,  $-NR^{16}(C_2-C_6)$  alkylene- $OR^{15}$ ,  $-NR^{17}R^{18}$ ,  $-(C_1-C_6)$  alkylene- $NR^{17}R^{18}$ ,  $-O-(C_2-C_6)$  alkylene- $NR^{17}R^{18}$ ,  $-NR^{16}-(C_2-C_6)$  alkylene- $NR^{17}R^{18}$ ,  $-(C_1-C_6)$  alkylene-

SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>-SO<sub>2</sub>-R<sup>15</sup>, -C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -C(O)-R<sup>15</sup>, -C(O)OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>;

R<sup>3</sup> is selected from halogen, cyano, amino, hydroxy, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>-SO<sub>2</sub>-R<sup>15</sup>, -C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -C(O)-R<sup>15</sup>, -C(O)OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>;

R<sup>4</sup> is selected from hydrogen, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-aryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, and -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup>;

R<sup>5</sup> is selected from hydrogen, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-aryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>15</sup>, and -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup>;

R<sup>7</sup> is independently selected from hydrogen, halogen, amino, hydroxy, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>15</sup>, -NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>R<sup>18</sup>, -SO<sub>2</sub>-R<sup>15</sup>, -SO<sub>2</sub>-R<sup>15</sup>, -SO<sub>2</sub>NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>-SO<sub>2</sub>-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>-SO<sub>2</sub>-R<sup>15</sup>, -C(O)-NR<sup>17</sup>R<sup>18</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>17</sup>R<sup>18</sup>, -NR<sup>16</sup>C(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -O-(C<sub>2</sub>-

C<sub>6</sub>) alkylene-NR<sup>16</sup>C(O)-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>17</sup>C(O)-R<sup>15</sup>, -C(O)-R<sup>15</sup>, -C(O)-OR<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-OR<sup>15</sup>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-OR<sup>15</sup>, -NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-OR<sup>15</sup>, -OC(O)-R<sup>15</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup>, -O-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup>, -NR<sup>16</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OC(O)-R<sup>15</sup> or -NR<sup>16</sup>-C(O)-OR<sup>15</sup>;

wherein

each of said -(C<sub>1</sub>-C<sub>6</sub>) alkyl or -(C<sub>1</sub>-C<sub>6</sub>) alkylene in R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> or R<sup>7</sup> is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;

each of said -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl or heteroaryl in R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> or R<sup>7</sup> is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;


R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> are each independently selected from hydrogen, -(C<sub>1</sub>-C<sub>6</sub>) haloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-heteroaryl, and -(C<sub>1</sub>-C<sub>6</sub>) alkylene-aryl; and/or two groups selected from R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> form together a cycle selected from -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl and heteroaryl;

wherein

each of said -(C<sub>1</sub>-C<sub>6</sub>) alkyl or -(C<sub>1</sub>-C<sub>6</sub>) alkylene in R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> or R<sup>18</sup> is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;

each of said -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl or heteroaryl in R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> or R<sup>18</sup> is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;

- **Y<sup>2</sup>** is a 5-membered heteroaryl selected from the following formulae



wherein **R<sup>12</sup>**, **R<sup>13</sup>** and **R<sup>14</sup>** are each independently selected from hydrogen, halogen, cyano, hydroxy, amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;

wherein each of said -(C<sub>1</sub>-C<sub>6</sub>) alkyl in **R<sup>12</sup>**, **R<sup>13</sup>** or **R<sup>14</sup>** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;

- **L** is selected from -(**CR<sup>10</sup>R<sup>11</sup>**)<sub>n</sub>, -(C<sub>4</sub>-C<sub>7</sub>) cycloalkyl and (C<sub>4</sub>-C<sub>7</sub>) heterocycloalkyl;

wherein

**n** is an integer selected from 1 or 2;

**R<sup>10</sup>** and **R<sup>11</sup>** are independently selected from hydrogen, halogen, hydroxy, amino, -(C<sub>1</sub>-C<sub>3</sub>) alkyl, -(C<sub>1</sub>-C<sub>2</sub>) haloalkyl, -(C<sub>1</sub>-C<sub>2</sub>) hydroxyalkyl, -(C<sub>1</sub>-C<sub>2</sub>) aminoalkyl, -O-(C<sub>1</sub>-C<sub>4</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>3</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>3</sub>) alkyl)<sub>2</sub>;

each of said -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl or (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl in **L** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -CH<sub>2</sub>-N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>6</sub>) alkyl, -NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl and -N-((C<sub>1</sub>-C<sub>6</sub>) alkyl)<sub>2</sub>;

- **Z<sup>1</sup>** is selected from -C(O)-**R<sup>9</sup>** and -SO<sub>2</sub>-**R<sup>9</sup>**;

wherein **R<sup>9</sup>** is selected from amino, -(C<sub>1</sub>-C<sub>6</sub>) alkyl, -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, aryl, heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-(C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-aryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-heteroaryl, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-OR<sup>21</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>23</sup>R<sup>24</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>23</sup>R<sup>24</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)-NR<sup>23</sup>R<sup>24</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-NR<sup>22</sup>-C(O)-R<sup>21</sup>, -(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>21</sup>, -OR<sup>21</sup>, -NR<sup>23</sup>R<sup>24</sup>, -NR<sup>22</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-OR<sup>21</sup>, -NR<sup>22</sup>-(C<sub>2</sub>-C<sub>6</sub>) alkylene-NR<sup>23</sup>R<sup>24</sup>, -NR<sup>22</sup>-(C<sub>1</sub>-C<sub>6</sub>) alkylene-C(O)OR<sup>21</sup>;

wherein

each of said  $-(C_1-C_6)$  alkyl or  $-(C_1-C_6)$  alkylene in  $R^9$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

each of said  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl or heteroaryl in  $R^9$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6) \text{ alkyl})_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  are each independently selected from hydrogen,  $-(C_1-C_6)$  alkyl,  $-(C_3-C_7)$  cycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  cycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  halocycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl, heteroaryl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  heterocycloalkyl,  $-(C_1-C_6)$  alkylene-heteroaryl, and  $-(C_1-C_6)$  alkylene-aryl; and/or two groups selected from  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  form together a cycle selected from  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl and heteroaryl;

wherein

each of said  $-(C_1-C_6)$  alkyl or  $-(C_1-C_6)$  alkylene in  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  or  $R^{24}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

each of said  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl, aryl or heteroaryl in  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  or  $R^{24}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6) \text{ alkyl})_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ; and

$-R^1$  is selected from hydrogen,  $-(C_1-C_6)$  alkyl,  $-(C_3-C_7)$  cycloalkyl,  $-(C_3-C_7)$  heterocycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  cycloalkyl,  $-(C_1-C_6)$  alkylene- $-(C_3-C_7)$  heterocycloalkyl,  $-(C_1-C_6)$  alkylene- $OR^{19}$  and  $-(C_1-C_6)$  alkylene- $NR^{19}R^{20}$ ,

wherein

$R^{19}$  and  $R^{20}$  are each independently selected from hydrogen,  $-(C_1-C_6)$  alkyl and  $-(C_3-C_7)$  cycloalkyl; or  $R^{19}$  and  $R^{20}$  form together a cycle selected from  $-(C_3-C_7)$  cycloalkyl and  $-(C_3-C_7)$  heterocycloalkyl;

each of said  $-(C_1-C_6)$  alkyl or  $-(C_1-C_6)$  alkylene in  $R^1$ ,  $R^{19}$  and  $R^{20}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6) \text{ alkyl})_2$ ;

each of said  $-(C_3-C_7)$  cycloalkyl or  $-(C_3-C_7)$  heterocycloalkyl in  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$  or  $R^{18}$  is optionally substituted with at least one group selected from halogen, cyano, hydroxy,

oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6)$  alkyl) $_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl, and  $-N-((C_1-C_6)$  alkyl) $_2$ ;

**R**<sup>1</sup> and one of **R**<sup>10</sup> or **R**<sup>11</sup> form together a (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl comprising at least one nitrogen atom;

wherein said (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl in **R**<sup>1</sup> and **R**<sup>10</sup> or **R**<sup>11</sup> is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6)$  alkyl) $_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6)$  alkyl) $_2$ ; or

**R**<sup>1</sup> and **R**<sup>9</sup> form together a (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl comprising at least one nitrogen atom;


wherein said (C<sub>3</sub>-C<sub>7</sub>) heterocycloalkyl in **R**<sup>1</sup> and **R**<sup>9</sup> is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino,  $-(C_1-C_6)$  alkyl,  $-CH_2-O-(C_1-C_6)$  alkyl,  $-CH_2-NH-(C_1-C_6)$  alkyl,  $-CH_2-N-((C_1-C_6)$  alkyl) $_2$ ,  $-O-(C_1-C_6)$  alkyl,  $-NH-(C_1-C_6)$  alkyl and  $-N-((C_1-C_6)$  alkyl) $_2$ ;

provided that

- when **Y**<sup>1</sup> is quinazolinyl and **R**<sup>1</sup> is hydrogen, then **Z**<sup>1</sup> is not selected from  $-C(O)$ -methyl and  $-S(O)_2$ -methyl;
- when **Y**<sup>1</sup> is 1*H*-pyrazolo[3,4-*d*]pyrimidinyl and **R**<sup>1</sup> is hydrogen, then **Z**<sup>1</sup> is not selected from  $-C(O)$ -methyl,  $-C(O)$ -*t*-butyl and  $-SO_2$ -methyl; and
- the compound of formula (I) is not N-(2-(5-(2-((5-methyloxazolo[4,5-*b*]pyridin-2-yl)thio)acetyl)thiophen-2-yl)ethyl)acetamide.


3. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 2, wherein **Y**<sup>1</sup> is a 9- or 10-membered bicyclic heteroaryl selected from:

the following formulae




wherein **A**<sup>1</sup>-**A**<sup>4</sup>, **A**<sup>6</sup>, **A**<sup>7</sup>, **G**<sup>1</sup> and **R**<sup>2</sup> are independently as defined in claim 2; and

the following formula




wherein **A<sup>8</sup>-A<sup>11</sup>** and **G<sup>2</sup>** are independently as defined in claim 2.

4. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 2, wherein **Y<sup>1</sup>** is a 10-membered [6,6] bicyclic heteroaryl selected from the following formulae



wherein **R<sup>2</sup>**, **R<sup>3</sup>** and **R<sup>7</sup>** are independently as defined in claim 2.

5. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 2 to 4, wherein **Y<sup>2</sup>** is selected from the following formulae



wherein **R<sup>12</sup>**, **R<sup>13</sup>** and **R<sup>14</sup>** are independently as defined in claim 2.

6. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 5, wherein  $R^{12}$  and  $R^{13}$  are each hydrogen.
7. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 2 to 6, wherein  $R^{10}$  and  $R^{11}$  are independently selected from hydrogen and (C<sub>1</sub>-C<sub>3</sub>) alkyl.
8. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 7, wherein  $R^{10}$  and  $R^{11}$  are each hydrogen.
9. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 2 to 8, wherein  $R^1$  is selected from hydrogen and (C<sub>1</sub>-C<sub>3</sub>) alkyl.
10. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 9, wherein  $R^1$  is hydrogen.
11. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 2 to 10, wherein  $n$  is 1.
12. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 2 to 11, wherein  $R^9$  is selected from methyl, *tert*-butyl, cyclopropyl, *O-tert*-butyl, hydroxymethyl, (S)-3,3,3-trifluoro-2-hydroxypropyl, 2-hydroxypropan-2-yl, 1-hydroxycyclopropyl, methoxymethyl, pyridin-2-ylmethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, phenylmethyl, phenyl, 2,2-difluorocyclopropyl and 2,2,3,3,3-pentafluoro-propyl, H<sub>2</sub>N-methyl, *N*-methyl-NH-methyl, *N*-methylazetidiny, 1-hydroxyethyl and pyrrolidinyl.
13. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 12, wherein  $R^9$  is selected from cyclopropyl, hydroxymethyl, (S)-3,3,3-trifluoro-2-hydroxypropyl, 2-hydroxypropan-2-yl, 1-hydroxycyclopropyl, 2,2-difluorocyclopropyl and 2,2,3,3,3-pentafluoro-propyl.
14. The use according to claim 1, wherein  $n$  is an integer selected from 1 and 2 and wherein  $R^{10}$  and  $R^{11}$  are independently selected from hydrogen and (C<sub>1</sub>-C<sub>3</sub>) alkyl, preferably  $R^{10}$  and  $R^{11}$  are each hydrogen.
15. The use according to claim 1, wherein said compound is selected from

|     |                                                                                                       |
|-----|-------------------------------------------------------------------------------------------------------|
| 99  | N-((5-(2-((2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide              |
| 100 | N-(2-(5-(2-((2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)acetamide             |
| 101 | N-(2-(5-(2-((2-cyclopropylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)acetamide                   |
| 102 | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide      |
| 103 | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide ; and |

|            |                                                                                           |
|------------|-------------------------------------------------------------------------------------------|
| <b>104</b> | N-(2-(5-(2-((5-methyloxazolo[4,5-b]pyridin-2-yl)thio)acetyl)thiophen-2-yl)ethyl)acetamide |
|------------|-------------------------------------------------------------------------------------------|

or a pharmaceutically acceptable salt and/or solvate thereof.

**16.** The use to claim **1**, wherein the medicament is for the treatment and/or prevention of an HDAC6-associated disease which is selected from inflammatory diseases, autoimmune diseases, proliferative diseases, neurodegenerative diseases, pains, neuropathies, psychiatric diseases, neurodevelopmental disorders, sleep disorders, cardiovascular diseases and metabolic or hormonal disorders.

**17.** The use according to claim **16**, wherein said HDAC6-associated disease is a neuropathy selected from Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), Charcot-Marie-Tooth disease, hereditary sensory and autonomic neuropathy, familial amyloidotic polyneuropathy, chemotherapy-induced peripheral neuropathy (CIPN) using chemotherapeutic anticancer agents, diabetic peripheral neuropathy (DPN), neuralgia, pain and/or neuropathic pain.

**18.** The use according to claim **16**, wherein said HDAC6-associated disease is a cardiovascular disease selected from chronic heart failure or acute heart failure, acute decompensated heart failure, ischemic heart disease, cardiomyopathy, myocarditis, valvular disease, hypertension, cardiac disease, tachycardia and congestive cardiac failure.

**19.** The use according to claim **16**, wherein said HDAC6-associated disease is an inflammatory disease is selected from the group comprising or consisting of acute pancreatitis, chronic pancreatitis, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, inflammatory bone disease, inflammatory pulmonary disease, inflammatory bowel disease, celiac disease, hepatitis, systemic inflammatory response syndrome (SIRS), postoperative or posttraumatic inflammation, pneumonia, nephritis, meningitis, cystitis, pharyngolaryngitis, gastric mucosal injury, spondylitis, arthritis, dermatitis, chronic pneumonia, bronchitis, pulmonary infarction, silicosis, pulmonary sarcoidosis, diabetic nephropathy, uveitis, suppurative hidradenitis, cerebrospinal meningitis, inflammatory bowel disease, ulcerative colitis and Crohn's disease.

**20.** The use according to claim **16**, wherein said HDAC6-associated disease is a metabolic or hormonal disorder selected from obesity, diabetes, acromegaly, infertility and metabolic syndrome.

**21.** The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim **2**, wherein said compound is selected from

|          |                                                                                   |
|----------|-----------------------------------------------------------------------------------|
| <b>1</b> | N-((5-(2-((2-isopropylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide |
|----------|-----------------------------------------------------------------------------------|

|    |                                                                                                                                        |
|----|----------------------------------------------------------------------------------------------------------------------------------------|
| 2  | N-((5-(2-((2-cyclopropylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                    |
| 3  | N-((5-(2-((2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                         |
| 4  | N-((5-(2-((2-(methoxymethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                |
| 5  | N-((5-(2-((1,6-dimethyl-1 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                 |
| 6  | N-((5-(2-((6-cyclopropyl-1-methyl-1 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide       |
| 7  | N-((5-(2-((2-methylpyrido[2,3- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                    |
| 8  | N-((5-(2-((7-chloro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                |
| 9  | N-((5-(2-((6-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                |
| 10 | N-((5-(2-((7-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                |
| 11 | N-((5-(2-((2,7-dimethylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                     |
| 12 | N-((5-(2-((7-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                               |
| 13 | N-((5-(2-((2-ethylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                          |
| 14 | N-((5-(2-((2-cyclobutylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                     |
| 15 | N-((5-(2-((8-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                |
| 16 | N-((5-(2-((2-(dimethylamino)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                |
| 17 | N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                               |
| 18 | N-((5-(2-((2-methylpyrido[3,2- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                    |
| 19 | N-((5-(2-((2-(difluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                               |
| 20 | N-((5-(2-((1-methyl-6-(trifluoromethyl)-1 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide |
| 21 | N-((5-(2-((6-(difluoromethyl)-1-methyl-1 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide  |
| 22 | N-((5-(2-((2-methyl-6-(trifluoromethyl)-2 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide |
| 23 | N-((5-(2-((5-methyloxazolo[4,5- <i>b</i> ]pyridin-2-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                     |
| 24 | 3-methyl-1-((5-(2-((1-methyl-1 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pyrrolidin-2-one      |
| 25 | 1-((5-(2-((1-methyl-1 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pyrrolidin-2-one               |
| 26 | 1-(2-(5-(2-((2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)pyrrolidin-2-one                                       |
| 27 | N-((2-(2-((1-methyl-1 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiazol-5-yl)methyl)pivalamide                      |
| 28 | N-((3-fluoro-5-(2-((1-methyl-1 <i>H</i> -pyrazolo[3,4- <i>d</i> ]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide            |
| 29 | N-(2-(5-(2-((2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)pivalamide                                             |

|    |                                                                                                                                                        |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30 | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)benzamide                                                        |
| 31 | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropanecarboxamide                                          |
| 32 | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-phenylacetamide                                               |
| 33 | N-methyl-N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                              |
| 34 | N-methyl-N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropanecarboxamide                                 |
| 35 | N-((5-(2-((2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropanecarboxamide                                                            |
| 36 | N-(2-(5-(2-((2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)cyclopropanecarboxamide                                                |
| 37 | N-(2-(5-(2-((2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)benzamide                                                              |
| 38 | N-((5-(2-((2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                                              |
| 39 | 2,2-difluoro-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide                                  |
| 40 | 2,2,3,3,3-pentafluoro-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide                                        |
| 41 | N-((5-(2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropanecarboxamide                      |
| 42 | 3,3,3-trifluoro-2-hydroxy-N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide                            |
| 43 | N-((5-(2-((2-cyclopropyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2,2-difluorocyclopropane-1-carboxamide |
| 44 | N-((5-(2-((2-cyclopropyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2,2,3,3,3-pentafluoropropanamide       |
| 45 | 1-hydroxy-N-((5-(2-((5-(trifluoromethyl)oxazolo[4,5-b]pyridin-2-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide                         |
| 46 | 3,3,3-trifluoro-2-hydroxy-N-((5-(2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide        |
| 47 | 1-hydroxy-N-((5-(2-((6-morpholino-2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide                       |
| 48 | 2-hydroxy-2-methyl-N-((5-(2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide               |
| 49 | 1-hydroxy-N-((5-(2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide         |
| 50 | 1-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide                                     |
| 51 | N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropanecarboxamide                                                  |
| 52 | 2-hydroxy-2-methyl-N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide                                   |
| 55 | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-(pyridin-2-yl)acetamide                                       |
| 56 | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-(pyridin-3-yl)acetamide                                       |

|    |                                                                                                                                    |
|----|------------------------------------------------------------------------------------------------------------------------------------|
| 57 | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-(pyridin-4-yl)acetamide                   |
| 58 | 2-methoxy-N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                          |
| 59 | 2-hydroxy-N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                          |
| 60 | 2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                  |
| 61 | 2-hydroxy-N-((5-(2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide      |
| 62 | N-((5-(2-((2-ethylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                                             |
| 63 | 2-hydroxy-N-((5-(2-((6-morpholino-2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                    |
| 64 | 2-hydroxy-N-((5-(2-((2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                |
| 65 | N-((5-(2-((2,6-dimethyl-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                      |
| 66 | 2-hydroxy-N-((5-(2-((2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                            |
| 67 | N-((5-(2-((6-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                                   |
| 68 | N-((5-(2-((7-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                                   |
| 69 | N-((5-(2-((6-(difluoromethyl)-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide       |
| 70 | 2-hydroxy-N-((5-(2-((7-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                  |
| 71 | 2-hydroxy-N-((5-(2-((6-(trifluoromethyl)oxazolo[5,4-c]pyridin-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                      |
| 72 | 2-hydroxy-N-((5-(2-((5-(trifluoromethyl)oxazolo[4,5-b]pyridin-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                      |
| 73 | N-((5-(2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                          |
| 74 | 2-hydroxy-N-((5-(2-((1-methyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide      |
| 75 | N-((5-(2-((7-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                         |
| 76 | 2-hydroxy-N-((5-(2-((2-methyl-6-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                        |
| 77 | N-((5-(2-((6-cyclopropoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                             |
| 78 | N-((5-(2-((6-((cyclopropylmethyl)amino)-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide               |
| 79 | N-((5-(2-((2-cyclopropyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide |
| 80 | 2-hydroxy-N-((5-(2-((6-methoxy-2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                       |
| 81 | 2-hydroxy-N-((5-(2-((2-methyl-6-morpholinoquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                               |
| 82 | 2-hydroxy-N-((5-(2-((2-methyl-6-(piperidin-1-yl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                         |
| 83 | 2-hydroxy-N-((5-(2-((2-methyl-6-(1,4-oxazepan-4-yl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                      |

|     |                                                                                                                                                   |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------|
| 84  | N-((5-(2-((6-(3,3-difluoropyrrolidin-1-yl)-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                           |
| 85  | 2-hydroxy-N-((5-(2-((2-methyl-6-(4-methylpiperazin-1-yl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                |
| 86  | 2-hydroxy-1-(3-(5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)pyrrolidin-1-yl)ethan-1-one                            |
| 87  | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)methanesulfonamide                                          |
| 88  | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)benzenesulfonamide                                          |
| 89  | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropanesulfonamide                                     |
| 90  | N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-1-phenylmethanesulfonamide                                 |
| 91  | N-methyl-N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropanesulfonamide                            |
| 92  | N-methyl-N-((5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-1-(pyridin-4-yl)methanesulfonamide                |
| 93  | 1-cyclopropyl-N-((5-(2-((2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)methanesulfonamide                                              |
| 94  | N-(2-(5-(2-((2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)methanesulfonamide                                                           |
| 95  | 1-(5-(1-(methylsulfonyl)pyrrolidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one                                    |
| 96  | 3-(5-(2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)pyrrolidine-1-sulfonamide                                           |
| 97  | N-((5-(2-((2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)methanesulfonamide                                                            |
| 98  | N-(2-(5-(2-((2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)methanesulfonamide                                                |
| 105 | 2-hydroxy-N-((5-(2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                            |
| 106 | N-((5-(2-((6-cyclopropyl-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                                             |
| 107 | 2-hydroxy-N-((5-(2-((7-methyl-2-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                    |
| 108 | N-((5-(2-((8-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                                        |
| 109 | 2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-N-methylacetamide                                        |
| 110 | 2,2-difluoro-N-((5-(2-((2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide                           |
| 111 | 2,2-difluoro-N-((5-(2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide |
| 112 | N-((5-(2-((7-cyclopropyl-2-(trifluoromethyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide               |
| 113 | 2-hydroxy-N-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                    |
| 114 | 2,2-difluoro-N-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide                |
| 115 | 3-hydroxy-1-(2-(5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)pyrrolidin-2-one                                         |

|     |                                                                                                                                         |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------|
| 116 | 2-hydroxy-N-methyl-N-((5-(2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide  |
| 117 | 2-hydroxy-N-((5-(2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                           |
| 118 | 2-hydroxy-N-((5-(2-((6-(trifluoromethyl)oxazolo[4,5-b]pyridin-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                           |
| 119 | 2-hydroxy-N-((5-(2-((2-methyl-6-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                 |
| 120 | 2,2-difluoro-N-((5-(2-((2-methyl-6-(trifluoromethoxy)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropane-1-carboxamide        |
| 121 | 2-hydroxy-N-((5-(2-((6-methoxy-2-methylpyrido[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                           |
| 122 | N-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)cyclopropanesulfonamide                      |
| 123 | 2,2,2-trifluoro-N-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)ethane-1-sulfonamide         |
| 124 | N-((5-(2-((6-fluoro-2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                            |
| 125 | 2-hydroxy-N-((5-(2-((1-(2-methoxyethyl)-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide |
| 126 | 2-hydroxy-N-((5-(2-((2-methyl-6-(trifluoromethoxy)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                            |
| 127 | N-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)ethanesulfonamide                            |
| 128 | (S)-2-hydroxy-N-(1-(5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)acetamide                                  |
| 129 | (S)-2-hydroxy-N-(1-(5-(2-((6-(trifluoromethyl)oxazolo[4,5-c]pyridin-2-yl)thio)acetyl)thiophen-2-yl)ethyl)acetamide                      |
| 130 | (S)-2-hydroxy-N-(1-(5-(2-((1-methyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)ethyl)acetamide      |
| 131 | 2-hydroxy-N-methyl-N-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                 |
| 132 | 2-hydroxy-N-((5-(2-((2-(2-methoxyethyl)-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide |
| 133 | N-((5-(2-((1-cyclopropyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide      |
| 134 | 2-hydroxy-N-((5-(2-((6-methoxy-2-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-methylpropanamide                 |
| 135 | N-((5-(2-((2-ethyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide            |
| 136 | N-((5-(2-((1-ethyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide            |
| 137 | 4-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)morpholin-3-one                                           |
| 138 | 4-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)morpholin-3-one                              |
| 139 | N-((5-(2-((2-(difluoromethyl)-6-methoxyquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                             |
| 140 | 2-hydroxy-N-((5-(2-((6-methoxy-2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                           |

|     |                                                                                                                                   |
|-----|-----------------------------------------------------------------------------------------------------------------------------------|
| 141 | 3-hydroxy-1-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pyrrolidin-2-one                          |
| 142 | N-((5-(2-((6-chloro-8-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                         |
| 143 | 2-hydroxy-N-((5-(2-((5-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                 |
| 144 | N-((5-(2-((6-ethoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                                  |
| 145 | N-((5-(2-((6-ethoxy-2-methylpyrido[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                      |
| 146 | N-((5-(2-((6-chloro-5-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                         |
| 147 | N-((5-(2-((6-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide   |
| 148 | 2-hydroxy-N-((5-(2-((8-methoxy-2-methyl-6-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide             |
| 149 | N-((5-(2-((6-(dimethylamino)-2-methylpyrido[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide             |
| 150 | N-((5-(2-((8-(dimethylamino)-2-methyl-6-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide     |
| 151 | 2-hydroxy-N-((5-(2-((2-methyl-8-(methylamino)-6-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide       |
| 152 | 2-hydroxy-N-((5-(2-((2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                    |
| 153 | 2-hydroxy-N-((5-(2-((2-methylpyrido[3,2-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                               |
| 154 | 2-hydroxy-N-((5-(2-((6-methoxy-2-(trifluoromethyl)pyrido[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide          |
| 155 | (S)-3-hydroxy-1-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pyrrolidin-2-one         |
| 156 | (R)-3-hydroxy-1-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pyrrolidin-2-one         |
| 157 | 1-((5-(2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pyrrolidin-2-one                       |
| 158 | N-((5-(2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                        |
| 159 | 2-hydroxy-N-((5-(2-((6-methoxy-2-(trifluoromethyl)pyrido[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-N-methylacetamide |
| 160 | N-((5-(2-((6-ethoxy-2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                      |
| 161 | 4-((5-(2-((6-methoxy-2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)morpholin-3-one                         |
| 162 | 2-hydroxy-N-((5-(2-((6-methoxy-2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-N-methylacetamide            |
| 163 | 2-methoxy-N-((5-(2-((6-methoxy-2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                     |
| 164 | N-((5-(2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide           |
| 165 | N-((5-(2-((1,7-naphthyridin-8-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                                             |
| 166 | N-((5-(2-((6-chloro-3H-imidazo[4,5-b]pyridin-2-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                            |

|     |                                                                                                                |
|-----|----------------------------------------------------------------------------------------------------------------|
| 167 | 2-hydroxy-N-((5-(2-((5-methoxybenzo[d]oxazol-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                   |
| 168 | 2-hydroxy-N-((5-(2-((4-methoxybenzo[d]oxazol-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                   |
| 169 | 2-hydroxy-N-((5-(2-((1-methyl-1H-benzo[d]imidazol-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide              |
| 170 | 2-hydroxy-N-((5-(2-((5-methylbenzo[d]oxazol-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                    |
| 171 | N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)tetrahydrofuran-2-carboxamide    |
| 172 | 2,2-difluoro-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide           |
| 173 | 2-hydroxy-N-((5-(2-((5-methoxy-3H-imidazo[4,5-b]pyridin-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide        |
| 174 | N-((5-(2-((5-chlorobenzo[d]oxazol-2-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                    |
| 176 | 2-hydroxy-N-((5-(2-(imidazo[1,2-a]pyrazin-8-ylthio)acetyl)thiophen-2-yl)methyl)acetamide                       |
| 177 | 2-amino-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                |
| 178 | N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-1-methylazetidine-3-carboxamide |
| 179 | N-((5-(2-((1,6-naphthyridin-5-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                          |
| 180 | N-((5-(2-((2,7-naphthyridin-1-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                          |
| 181 | 2-hydroxy-N-((5-(2-(imidazo[1,5-a]pyrazin-8-ylthio)acetyl)thiophen-2-yl)methyl)acetamide                       |
| 182 | 2-hydroxy-N-((5-(2-(pyrazolo[1,5-a]pyrazin-4-ylthio)acetyl)thiophen-2-yl)methyl)acetamide                      |
| 183 | N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-(methylamino)acetamide        |
| 184 | N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)pyrrolidine-2-carboxamide        |
| 185 | (S)-2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide        |
| 186 | (R)-2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide        |
| 189 | 3-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-1,1-dimethylurea                |
| 190 | tert-butyl ((5-(2-((6-methoxy-2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)carbamate   |
| 191 | N-((5-(2-((3-(trifluoromethyl)isoquinolin-1-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                     |
| 192 | N-((5-(2-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)acetyl)-1,3,4-thiadiazol-2-yl)methyl)pivalamide        |
| 193 | N-((5-(2-(phthalazin-1-ylthio)acetyl)thiophen-2-yl)methyl)pivalamide                                           |
| 194 | N-((5-(2-((4-methylphthalazin-1-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide                                 |
| 195 | N-((5-(2-((4-(trifluoromethyl)phthalazin-1-yl)thio)acetyl)thiophen-2-yl)methyl)pivalamide); and                |
| 196 | 2-hydroxy-N-((5-(2-((4-(trifluoromethyl)benzo[d]oxazol-2-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide         |


or a pharmaceutically acceptable salt and/or solvate thereof.

**22.** The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 2, wherein said compound is selected from

|            |                                                                                                                                    |
|------------|------------------------------------------------------------------------------------------------------------------------------------|
| <b>60</b>  | 2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                                  |
| <b>61</b>  | 2-hydroxy-N-((5-(2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide      |
| <b>73</b>  | N-((5-(2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                          |
| <b>74</b>  | 2-hydroxy-N-((5-(2-((1-methyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide      |
| <b>76</b>  | 2-hydroxy-N-((5-(2-((2-methyl-6-(trifluoromethyl)quinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                        |
| <b>79</b>  | N-((5-(2-((2-cyclopropyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide |
| <b>81</b>  | 2-hydroxy-N-((5-(2-((2-methyl-6-morpholinoquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                               |
| <b>135</b> | N-((5-(2-((2-ethyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide       |
| <b>147</b> | N-((5-(2-((6-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide    |
| <b>152</b> | 2-hydroxy-N-((5-(2-((2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide                     |
| <b>158</b> | N-((5-(2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide                         |
| <b>185</b> | (S)-2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide                            |
| <b>186</b> | (R)-2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propenamide; and                       |


or a pharmaceutically acceptable salt and/or solvate thereof.

**23.** The compound according to claim 2, which is 2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide:




or a salt and/or solvate thereof.

**24.** The compound according to claim 2, which is N-((5-(2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide:




or a salt and/or solvate thereof.

**25.** The compound according to claim **2**, which is 2-hydroxy-N-((5-(2-((2-methyl-6-morpholinoquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)acetamide:




or a salt and/or solvate thereof.

**26.** The compound according to claim **2**, which is N-((5-(2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)-2-hydroxyacetamide:



or a salt and/or solvate thereof.


**27.** The compound according to claim **2**, which is (R)-2-hydroxy-N-((5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)methyl)propanamide:



or a salt and/or solvate thereof.


**28.** A **process for manufacturing** a compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **2** to **13** and **21** to **27**, wherein said process comprises a step of reacting:

(i) a linear or cyclic amine of formula **T-9**:



with an acyl chloride of formula  $R^9\text{-COCl}$ , a carboxylic acid of formula  $R^9\text{-COOH}$  or sulfonyl chloride of formula  $R^9\text{-SO}_2\text{Cl}$ ; or

(ii) a halo-ketone of formula **T-13**:



with a thiol of formula  $Y^1\text{-SH}$ ,


wherein

$Y^1$ ,  $Y^2$ ,  $R^1$ ,  $R^9$  and  $Z^1$  are as defined in claim 2 and X is halo.

**29. A pharmaceutical composition** comprising a compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 2 to 13 and 21 to 27 and at least one pharmaceutically acceptable carrier.

**30.** the compound according to any one of claims 2 to 13 and 21 to 27 or the pharmaceutical composition according to claim 29 for use as a medicament.

**31.** A compound of formula **T-9**:



wherein  $Y^1$ ,  $Y^2$  and  $R^1$  are as defined in claim 2.